<DOC>
	<DOCNO>NCT00814164</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , clofarabine daunorubicin , work different way stop growth cancer cell , either kill cell stop divide . Giving clofarabine together daunorubicin may kill cancer cell . PURPOSE : This phase II trial study well give clofarabine together daunorubicin work treat old patient newly diagnose acute myeloid leukemia .</brief_summary>
	<brief_title>Clofarabine Daunorubicin Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Study complete response ( CR ) CR without platelet recovery ( CRp ) follow treatment clofarabine daunorubicin hydrochloride old patient newly diagnose acute myeloid leukemia . Secondary - Study disease-free overall survival patient follow treatment regimen . - Compare disease-free overall survival patient whose cell demonstrate apoptosis follow treatment regimen . OUTLINE : - Induction therapy : Patients receive clofarabine IV 1 hour day 1-5 daunorubicin hydrochloride IV 5 minute day 1 , 3 , 5 . Patients assessed induction course 1 . Patients ≥ 5 % blast bone marrow may receive another course induction therapy begin 28-84 day initiation course 1 . Patients achieve complete remission ( CR ) CR without platelet recovery ( CRp ) ( 1 2 course induction therapy ) proceed consolidation therapy . - Consolidation therapy : Beginning 28 -84 day initiation last course induction therapy , patient receive clofarabine IV 1 hour day 1-3 daunorubicin hydrochloride IV 5 minute day 1 3 . Patients may receive second course consolidation therapy begin 28-84 day consolidation course 1 . Blood bone marrow sample collect periodically assess response pharmacokinetic , cytogenetic , immunophenotyping , molecular analysis . After completion study treatment , patient follow least 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute myeloid leukemia At least 10 % blast peripheral blood De novo secondary disease No acute promyelocytic leukemia [ 15 ; 17 ] variant No clinical evidence CNS disease PATIENT CHARACTERISTICS : ECOG performance status 02 Serum bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN LVEF ≥ 45 % Estimated glomerular filtration rate ≥ 50 mL/min Not pregnant nursing Fertile patient must use effective barrier contraception least 6 month follow study treatment No known HIV positivity Able comply study procedure followup examination No psychiatric disorder would interfere consent , study participation , followup No uncontrolled systemic fungal , bacterial , viral , infection ( i.e. , exhibit ongoing signs/symptoms related infection without improvement despite appropriate antibiotic treatment ) No history serious organ dysfunction disease involve heart , kidney , liver , organ system may place patient undue risk undergo induction therapy agents No malignancy , unless diseasefree least 3 year follow curative intent therapy Nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia , regardless diseasefree duration , allow definitive treatment condition complete Patients organconfined prostate cancer evidence recurrent progressive disease base prostatespecific antigen value also eligible study hormonal therapy initiate radical prostatectomy perform No severe concurrent disease PRIOR CONCURRENT THERAPY : No concurrent systemic antileukemic therapy ( standard investigational ) No concurrent cytotoxic therapy investigational therapy No concurrent alternative medication ( e.g. , herbal botanical anticancer purpose ) No prior chemotherapy Prior hydroxyurea allow</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>